Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 8 | 2022 | 83 | 4.100 |
Why?
|
| Kidney Transplantation | 8 | 2022 | 128 | 3.550 |
Why?
|
| Organ Transplantation | 4 | 2022 | 39 | 1.740 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 63 | 1.620 |
Why?
|
| Cytomegalovirus | 5 | 2022 | 78 | 1.560 |
Why?
|
| Graft Rejection | 6 | 2017 | 75 | 1.540 |
Why?
|
| Transplant Recipients | 6 | 2022 | 23 | 1.380 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 9 | 1.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 132 | 1.040 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 14 | 1.030 |
Why?
|
| Patient Readmission | 3 | 2015 | 132 | 1.000 |
Why?
|
| Retrospective Studies | 14 | 2022 | 3664 | 0.920 |
Why?
|
| Antimicrobial Stewardship | 1 | 2022 | 10 | 0.840 |
Why?
|
| Daptomycin | 1 | 2022 | 13 | 0.840 |
Why?
|
| Inpatients | 3 | 2022 | 150 | 0.790 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 185 | 0.790 |
Why?
|
| Antiviral Agents | 3 | 2022 | 135 | 0.790 |
Why?
|
| Immunosuppressive Agents | 4 | 2016 | 139 | 0.770 |
Why?
|
| Hypoglycemia | 1 | 2020 | 14 | 0.730 |
Why?
|
| Antifungal Agents | 2 | 2018 | 39 | 0.710 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 42 | 0.700 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 60 | 0.700 |
Why?
|
| Electronic Health Records | 1 | 2020 | 69 | 0.690 |
Why?
|
| Adult | 14 | 2022 | 8945 | 0.680 |
Why?
|
| Lung Transplantation | 2 | 2016 | 18 | 0.640 |
Why?
|
| Cryptococcosis | 1 | 2018 | 5 | 0.610 |
Why?
|
| Humans | 26 | 2023 | 31059 | 0.610 |
Why?
|
| Population Health | 1 | 2018 | 5 | 0.610 |
Why?
|
| Consensus | 1 | 2018 | 112 | 0.590 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 160 | 0.590 |
Why?
|
| Ustilaginales | 1 | 2017 | 1 | 0.580 |
Why?
|
| Yeasts | 1 | 2017 | 3 | 0.580 |
Why?
|
| Dermatomycoses | 1 | 2017 | 3 | 0.580 |
Why?
|
| Fungemia | 1 | 2017 | 8 | 0.570 |
Why?
|
| Exanthema | 1 | 2017 | 16 | 0.570 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.560 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 10 | 0.560 |
Why?
|
| Roseolovirus Infections | 1 | 2016 | 4 | 0.550 |
Why?
|
| United States | 6 | 2022 | 2376 | 0.550 |
Why?
|
| Risk Factors | 7 | 2022 | 2587 | 0.540 |
Why?
|
| Bacteremia | 1 | 2016 | 119 | 0.520 |
Why?
|
| Middle Aged | 12 | 2020 | 10235 | 0.500 |
Why?
|
| Liver Failure | 1 | 2015 | 11 | 0.500 |
Why?
|
| HIV Infections | 2 | 2022 | 886 | 0.500 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 14 | 0.490 |
Why?
|
| Heart Transplantation | 1 | 2014 | 38 | 0.480 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 23 | 0.470 |
Why?
|
| Liver Transplantation | 1 | 2015 | 80 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 420 | 0.440 |
Why?
|
| Male | 14 | 2020 | 16488 | 0.430 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 104 | 0.430 |
Why?
|
| Aged | 8 | 2022 | 10077 | 0.410 |
Why?
|
| Immunocompromised Host | 3 | 2017 | 50 | 0.400 |
Why?
|
| Lemierre Syndrome | 1 | 2011 | 1 | 0.380 |
Why?
|
| Time Factors | 5 | 2016 | 1679 | 0.380 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 367 | 0.370 |
Why?
|
| Incidence | 3 | 2021 | 783 | 0.360 |
Why?
|
| Young Adult | 5 | 2018 | 2057 | 0.350 |
Why?
|
| Ganciclovir | 2 | 2022 | 28 | 0.350 |
Why?
|
| Hospital Mortality | 3 | 2015 | 150 | 0.350 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 344 | 0.340 |
Why?
|
| Postoperative Complications | 1 | 2016 | 996 | 0.330 |
Why?
|
| Female | 11 | 2018 | 17005 | 0.310 |
Why?
|
| Directly Observed Therapy | 1 | 2006 | 2 | 0.280 |
Why?
|
| Graft Survival | 2 | 2017 | 98 | 0.270 |
Why?
|
| HIV Seropositivity | 1 | 2006 | 83 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 130 | 0.270 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 159 | 0.240 |
Why?
|
| Linezolid | 1 | 2022 | 6 | 0.210 |
Why?
|
| Comorbidity | 2 | 2014 | 507 | 0.210 |
Why?
|
| Carbapenems | 1 | 2022 | 31 | 0.210 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 44 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 115 | 0.210 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 54 | 0.210 |
Why?
|
| Virus Diseases | 1 | 2022 | 16 | 0.200 |
Why?
|
| Benchmarking | 1 | 2022 | 46 | 0.200 |
Why?
|
| Vancomycin | 1 | 2022 | 59 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 1936 | 0.200 |
Why?
|
| Pancreas Transplantation | 1 | 2021 | 17 | 0.200 |
Why?
|
| Medicare | 1 | 2022 | 127 | 0.190 |
Why?
|
| Pancreas | 1 | 2021 | 37 | 0.190 |
Why?
|
| Rectal Prolapse | 1 | 2021 | 4 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 59 | 0.190 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 23 | 0.190 |
Why?
|
| Adolescent | 2 | 2018 | 2400 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 74 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2016 | 2041 | 0.180 |
Why?
|
| Kidney | 1 | 2021 | 181 | 0.170 |
Why?
|
| Insulin | 1 | 2020 | 97 | 0.170 |
Why?
|
| Laparoscopy | 1 | 2021 | 171 | 0.170 |
Why?
|
| HIV-1 | 1 | 2022 | 456 | 0.160 |
Why?
|
| Biomarkers | 1 | 2022 | 734 | 0.160 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2018 | 2 | 0.150 |
Why?
|
| Saccharomyces | 1 | 2017 | 1 | 0.140 |
Why?
|
| Idarubicin | 1 | 2017 | 1 | 0.140 |
Why?
|
| Echinocandins | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cryptococcus | 1 | 2017 | 2 | 0.140 |
Why?
|
| Trichosporon | 1 | 2017 | 2 | 0.140 |
Why?
|
| Amphotericin B | 1 | 2017 | 6 | 0.140 |
Why?
|
| Cytarabine | 1 | 2017 | 11 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 10 | 0.140 |
Why?
|
| Lipopeptides | 1 | 2017 | 12 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 34 | 0.140 |
Why?
|
| Vidarabine | 1 | 2017 | 12 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5196 | 0.140 |
Why?
|
| Voriconazole | 1 | 2017 | 11 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 12 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 40 | 0.140 |
Why?
|
| Paecilomyces | 1 | 2016 | 2 | 0.140 |
Why?
|
| Fever | 1 | 2017 | 42 | 0.140 |
Why?
|
| Herpesvirus 7, Human | 1 | 2016 | 2 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 1 | 2016 | 4 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 10 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 7 | 0.140 |
Why?
|
| Medicare Part D | 1 | 2016 | 8 | 0.130 |
Why?
|
| Dyspnea | 1 | 2016 | 44 | 0.130 |
Why?
|
| Pharmacoepidemiology | 1 | 2016 | 5 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 249 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 24 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 61 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 115 | 0.130 |
Why?
|
| California | 1 | 2014 | 31 | 0.120 |
Why?
|
| Florida | 1 | 2014 | 22 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 337 | 0.120 |
Why?
|
| Income | 1 | 2014 | 79 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2015 | 353 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2021 | 3808 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 924 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2014 | 225 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1134 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 872 | 0.100 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 12 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2011 | 9 | 0.100 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 10 | 0.090 |
Why?
|
| Astacoidea | 1 | 2009 | 1 | 0.090 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.090 |
Why?
|
| Paragonimiasis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Paragonimus westermani | 1 | 2009 | 1 | 0.090 |
Why?
|
| Shellfish | 1 | 2009 | 3 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 164 | 0.090 |
Why?
|
| Genotype | 1 | 2011 | 428 | 0.090 |
Why?
|
| Urban Health | 1 | 2006 | 23 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2006 | 99 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2006 | 158 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 427 | 0.060 |
Why?
|
| Hospitalization | 1 | 2006 | 336 | 0.060 |
Why?
|
| Health Facilities | 1 | 2023 | 18 | 0.050 |
Why?
|
| Proviruses | 1 | 2022 | 9 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 33 | 0.050 |
Why?
|
| Virus Latency | 1 | 2022 | 18 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 33 | 0.050 |
Why?
|
| Perineum | 1 | 2021 | 8 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2021 | 81 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 165 | 0.050 |
Why?
|
| Infection Control | 1 | 2022 | 177 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 274 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 164 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 9 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 10 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 30 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 30 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 375 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 407 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2016 | 70 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 224 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 818 | 0.030 |
Why?
|
| Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
|
| Praziquantel | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Food Contamination | 1 | 2009 | 4 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 8 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 27 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2009 | 25 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 409 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 4713 | 0.010 |
Why?
|